{"organizations": [], "uuid": "5e4fe32fec10de91e7193a181e8f6694a76054f9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-chromadex-patent-trial-and-appeal/brief-chromadex-patent-trial-and-appeal-board-of-u-s-patent-and-trademark-office-denied-elysium-healths-request-to-invalidate-u-s-patent-idUSFWN1PH0MF", "country": "US", "domain_rank": 408, "title": "BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T13:43:00.000+02:00", "replies_count": 0, "uuid": "5e4fe32fec10de91e7193a181e8f6694a76054f9"}, "author": "", "url": "https://www.reuters.com/article/brief-chromadex-patent-trial-and-appeal/brief-chromadex-patent-trial-and-appeal-board-of-u-s-patent-and-trademark-office-denied-elysium-healths-request-to-invalidate-u-s-patent-idUSFWN1PH0MF", "ord_in_thread": 0, "title": "BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "appeal board of u.s. patent and trademark office denied elysium health", "sentiment": "negative"}, {"name": "request to invalidate u.s. patent reuters", "sentiment": "none"}, {"name": "trademark office denied elysium health", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "chromadex corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News January 22, 2018 / 11:45 AM / in 9 hours BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent Reuters Staff 1 Min Read \nJan 22 (Reuters) - Chromadex Corp: \n* CHROMADEX - PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE DENIED ELYSIUM HEALTH INC.â€˜S REQUEST TO INVALIDATE U.S. PATENT \n* CHROMADEX - U.S. PATENT COVERING COMPOSITIONS COMPRISING NICOTINAMIDE RIBOSIDE, WHICH CHROMADEX CURRENTLY LICENSES FROM TRUSTEES OF DARTMOUTH COLLEGE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T13:43:00.000+02:00", "crawled": "2018-01-22T14:04:53.014+02:00", "highlightTitle": ""}